Northwire Canada EditionFriday, October 16, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4192.70 +0.5% SILVER 57.49 +0.6% COPPER 6.59 +0.5% OIL 96.48 −1.5% PALLADIUM 1120.25 −0.7% MON 0.385 −6.1% OMI 0.255 +2.0% BUFF 0.800 +2.6% FEO 0.670 +3.1% LIB 0.710 −1.4% NPR 0.640 +3.2% QZM 0.380 +0.0% BVA 0.750 −1.3% ONAU 0.530 +1.9% FMR 0.225 +0.0% GSVR 0.350 +2.9% PHNM 0.345 +1.5% SLG 5.62 −1.6% CASA 0.065 +8.3% DRY 0.220 +2.3% SOMA 0.580 +3.6% GOLD 4192.70 +0.5% SILVER 57.49 +0.6% COPPER 6.59 +0.5% OIL 96.48 −1.5% PALLADIUM 1120.25 −0.7% MON 0.385 −6.1% OMI 0.255 +2.0% BUFF 0.800 +2.6% FEO 0.670 +3.1% LIB 0.710 −1.4% NPR 0.640 +3.2% QZM 0.380 +0.0% BVA 0.750 −1.3% ONAU 0.530 +1.9% FMR 0.225 +0.0% GSVR 0.350 +2.9% PHNM 0.345 +1.5% SLG 5.62 −1.6% CASA 0.065 +8.3% DRY 0.220 +2.3% SOMA 0.580 +3.6%

Healthcare

Page 57
  1. Feb 23, 2026 · 21:40 · SURE

    Surenano Science closes acquisition of GlucaPharm

    Surenano Science closes acquisition of GlucaPharm

    01
  2. Feb 23, 2026 · 17:59 · BHC

    Bausch Health launches Clear + Brilliant in Canada

    Bausch Health launches Clear + Brilliant in Canada

    02
  3. Feb 23, 2026 · 09:01 · SURE

    SureNano Science Ltd. Acquires GlucaPharm Inc., Advancing Second-Generation FDA Pathway GLP-1 Drug Development

    SureNano Science Ltd. Acquires GlucaPharm Inc., Advancing Second-Generation FDA Pathway GLP-1 Drug Development

    03
  4. Feb 23, 2026 · 08:00 · BHC

    Bausch Health's Aesthetics Business, Solta Medical, Announces the Launch of Clear + Brilliant(TM) Touch Laser in Canada

    Bausch Health's Aesthetics Business, Solta Medical, Announces the Launch of Clear + Brilliant(TM) Touch Laser in Canada

    04
  5. Feb 20, 2026 · 20:38 · ASEP

    Asep Medical's Hancock resigns as CEO, chairman

    Asep Medical's Hancock resigns as CEO, chairman

    05
  6. Feb 20, 2026 · 20:02 · RKV

    Rakovina Therapeutics increases financing

    Rakovina Therapeutics increases financing

    06
  7. Feb 20, 2026 · 19:50 · RKV

    Rakovina Therapeutics Announces Upsized Financing Up to $2.0 Million

    Rakovina Therapeutics Announces Upsized Financing Up to $2.0 Million

    07
  8. Feb 20, 2026 · 18:03 · EPRX

    Eupraxia Pharmaceuticals closes $63.2M (U.S.) offering

    Eupraxia Pharmaceuticals closes $63.2M (U.S.) offering

    08
  9. Feb 20, 2026 · 17:01 · DTR

    DiagnosTear Advances UK Market Entry Through Commercial Collaboration with Hanson Medical

    DiagnosTear Advances UK Market Entry Through Commercial Collaboration with Hanson Medical

    09
  10. Feb 20, 2026 · 15:15 · KNE

    Kane publishes article in International Wound Journal

    Kane publishes article in International Wound Journal

    10
  11. Feb 20, 2026 · 12:10 · AFV

    Apolo V Acquisition Corp. Amendment to Definitive Agreement with TelyRx, Inc. and Rescheduling of Special Meeting of Shareholders

    Apolo V Acquisition Corp. Amendment to Definitive Agreement with TelyRx, Inc. and Rescheduling of Special Meeting of Shareholders

    11
  12. Feb 20, 2026 · 07:25 · KNE

    Kane Biotech Announces Publication of revyve(TM) Wound Gel Article in the International Wound Journal

    Kane Biotech Announces Publication of revyve(TM) Wound Gel Article in the International Wound Journal

    12
  13. Feb 20, 2026 · 07:03 · FRX

    Fennec Pharmaceuticals Presents Real World Data Supporting the Integration and Clinical Use of PEDMARK(TM) in Treating Adults with Head & Neck Cancers

    Fennec Pharmaceuticals Presents Real World Data Supporting the Integration and Clinical Use of PEDMARK(TM) in Treating Adults with Head & Neck Cancers

    13
  14. Feb 20, 2026 · 07:01 · TLT

    Correcting and Replacing: Theralase Bladder Cancer Clinical Data to be Presented at the 2026 European Association of Urology Congress

    Correcting and Replacing: Theralase Bladder Cancer Clinical Data to be Presented at the 2026 European Association of Urology Congress

    14
← Newer Older →